A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The study involves a single injection of LY2963016 and a single injection of Lantus, on 2
separate occasions in participants with type I diabetes. Following each dose, participants
will undergo a glucose clamp which lasts for 42 hours each time. There will be at least 7
days between the two periods, during which time there will be no study treatment, but
participants will resume their regular therapy. The duration of this study can be up to 9.5
weeks. The purposes of this study are to understand how the blood sugar lowering effect of
LY2963016 compares to that of Lantus, and to determine how LY2963016 and Lantus are
metabolized by participants with type I diabetes.